SELLAS Life Sciences Group, Inc. develops novel cancer therapeutics as a late-stage clinical biopharmaceutical company. News about SLS centers on its acute myeloid leukemia programs, including galinpepimut-S (GPS), a WT1-directed peptide immunotherapy evaluated in the REGAL Phase 3 trial, and SLS009 (tambiciclib), a selective CDK9 inhibitor studied in AML settings.
Recurring updates include clinical and preclinical data presentations, trial progress, regulatory and corporate updates, financial results, cash-position disclosures, warrant exercises, and other capital-structure developments tied to funding its oncology pipeline.
SELLAS Life Sciences Group has received approval for the Phase 3 REGAL study of galinpepimut-S in acute myeloid leukemia (AML) patients, allowing enrollment in France. The company strengthened its balance sheet with a $9.2 million financing, aimed at supporting ongoing clinical studies. Net loss for Q3 2020 was $4.5 million, a decrease from $11.5 million in Q3 2019. Cash and cash equivalents stood at approximately $8.2 million as of September 30, 2020. Challenges due to COVID-19 are affecting patient enrollment timelines.
SELLAS Life Sciences Group (SLS) announced the approval of its Investigational Medicinal Product Dossier (IMPD) by the French regulatory authority for its Phase 3 REGAL study of galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) patients who have achieved complete remission. This milestone allows for increased patient enrollment in France. Previous data from a Phase 2 study indicated a median overall survival of 21.0 months for GPS-treated patients, compared to 5.4 months with standard care. The REGAL study aims to evaluate overall survival and other key clinical endpoints.
SELLAS Life Sciences Group (SLS) recently strengthened its balance sheet with a $9.2 million private placement. The company is advancing its clinical programs for galinpepimut-S, including the Phase 3 REGAL study for AML, expected to yield multiple data readouts within 18 months. R&D expenses rose to $2.3 million in Q2 2020, compared to $1.4 million in Q2 2019, primarily due to REGAL study costs. The net loss for Q2 2020 was $4.4 million, or $0.66 per share, slightly increased from $4.1 million in Q2 2019. As of June 30, 2020, cash and cash equivalents stood at $3.3 million.
SELLAS Life Sciences Group (Nasdaq: SLS) announced on July 31, 2020, a private placement to raise approximately $9.2 million by offering up to 2,744,078 shares of common stock and accompanying warrants, priced at $3.335 per share. The transaction closing is expected on August 4, 2020, subject to customary conditions. Maxim Group LLC is the sole placement agent. The securities will not be registered under the Securities Act and are offered only to accredited investors. SELLAS is focused on innovative cancer immunotherapies, including its lead candidate, galinpepimut-S.
SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) has announced its 2020 Annual Meeting of Stockholders will be held virtually on June 9, 2020, at 8:30 a.m. Eastern Time due to COVID-19. Stockholders of record by April 13, 2020, can vote and ask questions online starting at 8:15 a.m. Eastern Time. Participation requires a 15-digit control number and the meeting password: SLS2020. Beneficial owners must register in advance with Computershare by June 4, 2020. Stockholders can submit questions prior to the meeting or during the live webcast.
SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) reported its Q1 2020 financial results, emphasizing its commitment to ongoing clinical trials despite the COVID-19 pandemic. The company focuses on developing cancer immunotherapies with key progress in its galinpepimut-S (GPS) and nelipepimut-S (NPS) programs. As of March 31, 2020, cash and cash equivalents stood at $6.7 million. The net loss for the quarter was $4.2 million, with a loss per share of $0.66. Positive follow-up data for GPS indicated a median overall survival of 21 months for AML patients, compared to 5.4 months for standard care.